CDKN1A and neoplasm: We show here that Plk1 inhibition activates the MAPK/Erk and PI3K/Akt pathways (Fig. 7B to E), likely responsible for increased p21 in the cytoplasm of HCT116 cells (Fig. 7D and E), leading further to the inhibition of apoptosis and survival of treated tumor cells.